small integral membrane protein 30Genealiases: LINC00998 · MAVI1
Q-omics provides the consensus-scored SMIM30 profile across patient tissues and cancer cell-line models. SMIM30 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, SMIM30 is differentially expressed in 10, with the highest sampling consensus in KICH. Additionally, SMIM30 RNA expression shows 18,022 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and KICH as cancer lineages where SMIM30 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SMIM30 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SMIM30 survival associations across molecular data types. SMIM30 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SMIM30 RNA expression–survival associations across cancer types. High SMIM30 expression shows unfavorable associations in UVM, HNSC, STAD, UCEC and LGG, but favorable associations in ACC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for SMIM30 RNA expression.
This table summarizes SMIM30 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for SMIM30. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SMIM30 shows lower tumor expression in KICH and higher tumor expression in KIRC, BLCA, HNSC, KIRP and CHOL. The KICH box plot shows higher SMIM30 RNA expression in normal versus tumor tissue (log2 FC = −1.671, t-test p < 0.001).
This table shows molecular features associated with SMIM30 in patient tissues and cancer cell lines. In patient samples, SMIM30 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, SMIM30 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia.
